515 related articles for article (PubMed ID: 34061567)
1. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
2. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
4. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
5. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
[TBL] [Abstract][Full Text] [Related]
7. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L
Cancer Cytopathol; 2019 Sep; 127(9):578-585. PubMed ID: 31386310
[TBL] [Abstract][Full Text] [Related]
9. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
[TBL] [Abstract][Full Text] [Related]
10. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays.
Pritchard JJG; Hamilton G; Hurst CD; Fraser S; Orange C; Knowles MA; Jones RJ; Leung HY; Iwata T
Urol Oncol; 2020 Sep; 38(9):737.e1-737.e10. PubMed ID: 32532529
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
16. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
18. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
[TBL] [Abstract][Full Text] [Related]
19. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
[TBL] [Abstract][Full Text] [Related]
20. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]